You're contacting media contact of this press release

Title: CoreAge Rx Releases Comprehensive Clinical Guide on Tirzepatide’s Role in Modern Weight Management

Wichita Falls, TX, United States, 18th May 2026 - CoreAge Rx has published an extensive new guide examining the impact of Tirzepatide on long-term weight management. This resource provides a detailed look at how dual-agonist therapy supports body composition and metabolic health for individuals pursuing longevity goals.The full guide is available at the original post: https://www.coreagerx.com/tirzepatide-before-and-after/.Alongside this publication, CoreAge Rx is introducing its Tirzepatide Microdosing Therapy. This protocol uses dual incretin activity to refine metabolic function, prioritizing long-term resilience and sustainable weight management over traditional high-dose methods.Dual Hormone Activation and Metabolic FunctionTirzepatide interacts with both GLP-1 and GIP receptors, creating a broader metabolic effect than therapies targeting a single pathway. The CoreAge Rx microdosing approach utilizes low doses to facilitate glucose regulation and energy balance. By emphasizing dual hormone activation, the therapy improves insulin response and nutrient partitioning, helping the body use carbohydrates and fats more efficiently for fuel.Core Benefits of the Microdosing ProtocolThe therapy is designed for individuals focused on physical performance and healthy aging. Key benefits include:Metabolic Flexibility: Enhances the body’s ability to process nutrients and maintain steady glucose levels.Body Composition Support: Promotes the maintenance of lean mass while supporting weight management.Energy and Vitality: Contributes to a balanced internal environment and improved energy levels.Precision Dosing: Minimizes the side-effect profile through carefully calibrated, low-level administration.Patient Experience and AccessibilityParticipants in the microdosing protocol typi...

This press release is issued by King Newswire